Review ArticleInfantile Hemangioma: A Current ReviewPahl, Kristy S. MD*; McLean, Thomas W. MD† Author Information *Department of Pediatrics, Duke University School of Medicine, Durham †Wake Forest School of Medicine, Winston-Salem, NC The authors declare no conflict of interest. Reprints: Thomas W. McLean, MD, Department of Pediatrics, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157 (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: March 2022 - Volume 44 - Issue 2 - p 31-39 doi: 10.1097/MPH.0000000000002384 Buy Metrics Abstract Infantile hemangiomas (IHs) are common vascular lesions which are benign but can cause significant functional and cosmetic morbidity. Since the fortuitous discovery of propranolol being effective to treat IH over a decade ago, the therapy and prognosis for children with IH have improved dramatically. Oral propranolol (as well as other oral beta-blockers and topical timolol) are safe and effective treatments, and have now supplanted other therapies. Making the correct diagnosis is crucial, because other vascular lesions can mimic IH. In addition, IH can be the first manifestation of an underlying syndrome. For IH requiring treatment, initiating treatment early is key to optimizing success. Therefore, early recognition and referral, if necessary, are important. Continued research on IH, both basic science and clinical, should result in continued advances. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.